Filed Pursuant to Rule 424(b)(3)
Registration No. 333-263798
PROSPECTUS SUPPLEMENT NO. 1
(To Prospectus dated April 14, 2023)
UP TO 17,141,926 SHARES OF COMMON STOCK
ISSUABLE UPON EXERCISE OF WARRANTS
UP TO 96,941,181 SHARES OF COMMON STOCK
UP TO 4,450,000 WARRANTS TO PURCHASE COMMON STOCK
This prospectus supplement
updates and supplements the prospectus, dated April 14, 2023 (as supplemented to date, the Prospectus), which forms a part of our registration statement on Form S-1 (No. 333-263798). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Quarterly Report on Form
10-Q for the quarter ended March 31, 2023 filed with the Securities and Exchange Commission on May 11, 2023 (the Quarterly Report). Accordingly, we have attached the Quarterly Report to
this prospectus supplement.
The Prospectus and this prospectus supplement relate to the issuance by us of up to an aggregate of 17,141,926 shares of our
common stock, $0.0001 par value per share (the common stock) consisting of (i) 4,450,000 shares of common stock issuable upon the exercise of 4,450,000 warrants (the private placement warrants) originally issued in a private
placement in connection with the initial public offering (the IPO) of Supernova Partners Acquisition Company II, Ltd., a Cayman Islands exempted company (Supernova), by the holders thereof, (ii) 8,624,972 shares of common
stock issuable upon the exercise of 8,624,972 warrants (the public warrants and, together with the private placement warrants, the warrants) originally issued in the IPO by holders thereof, and (iii) 4,066,954 shares of
common stock issuable upon the exercise of warrants assumed by us and converted into warrants to purchase common stock (the Rigetti assumed warrants) in connection with the Business Combination (as defined below). We will receive the
proceeds from the exercise of any warrants and any Rigetti assumed warrants for cash.
The Prospectus and this prospectus supplement also relate to the
offer and sale from time to time by the selling securityholders named in this prospectus or their permitted transferees (the selling securityholders) of up to (i) 96,941,181 shares of common stock consisting of (a) 10,251,000 shares of
common stock purchased by subscribers at a price of $10.00 per share and 4,390,244 shares of common stock purchased by subscribers at a price of $10.25 per share in private placements pursuant to separate subscription agreements, (b) 8,625,000
shares of common stock (the Founder Shares) originally purchased by Supernova Partners II LLC (Supernova Sponsor) for $25,000, or for approximately $0.004 per share, in a private placement in connection with the IPO,
including 3,059,273 Founder Shares subject to vesting and forfeiture (the Sponsor Vesting Shares), (c) 4,450,000 shares of common stock issuable upon exercise of the private placement warrants, (d) 2,446,716 shares of common stock
issuable pursuant to the exercise of Rigetti assumed warrants, which Rigetti assumed warrants have a weighted average exercise price of $0.0957 per share, (e) 6,226,065 shares of common stock issuable upon exercise of outstanding options, which
have an exercise price of $0.272 per share, (f) 6,288,369 shares of common stock issuable in connection with the vesting and settlement of outstanding restricted stock units, which were assumed by and converted into restricted stock awards for
common stock in connection with the Business Combination based on an acquiror share value of $10.00 per share and (g) 54,263,787 shares of common stock issued in connection with the Business Combination as merger consideration at an acquiror share
value of $10.00 per share, and (ii) up to 4,450,000 private placement warrants, which were originally purchased by Supernova Sponsor at a price of $2.00 per warrant. We will not receive any proceeds from the sale of shares of common stock or
warrants by the selling securityholders pursuant to this prospectus.
This prospectus supplement updates and supplements the information in the Prospectus
and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement is qualified by reference to the Prospectus, including any
amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and supersedes the information contained therein.
Our common stock and public warrants are listed on the Nasdaq Capital Market under the symbols RGTI and RGTIW, respectively. On
May 10, 2023, the last reported sales price of our common stock was $0.4874 per share and the last reported sales price of our public warrants was $0.0882 per warrant.
We are an emerging growth company as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company
reporting requirements. The Prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in our securities involves a high degree of risks. You should review carefully the risks and uncertainties described in the
section titled Risk Factors beginning on page 16 of the Prospectus, and under similar headings in any amendments or supplements
to the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the
accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.
The date of this
prospectus supplement is May 11, 2023.